How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Open accessThe DOI matches its Crossref record; 90 of the 92 references it cites were found in a registry or an index.
Abstract
We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006-August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general social anxiety, posttraumatic stress disorder, anorexia nervosa, attention-deficit hyperactivity disorder, and Tourette`s disorder. Outcome variables were too heterogeneous to conduct a meta-analysis. A narrative synthesis method was applied. The study quality was assessed using the risk-of-bias tool and SIGN-checklists. THC- and CBD-based medicines, given as adjunct to pharmaco- and psychotherapy, were associated with improvements of several symptoms of mental disorders, but not with remission. Side effects occurred, but severe adverse effects were mentioned in single cases only. In order to provide reliable treatment recommendations, more and larger RCTs with follow-up assessments, consistent outcome measures and active comparisons are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous systematic reviews have been limited in their coverage of all relevant diseases, but most importantly primarily ignored the fact that medical cannabinoid products—a term that encompasses all plant-derived and synthetic derivatives—differ in their pharmacology [1–5].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & The PRISMA Group (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000097 · Cited by 64,042
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
Wang, G., Ma, R., Qiao, G., Wada, K., Aizawa, Y., & Satoh, T. (2015) · Integrative Medicine International · doi:10.1159/000368408 · Cited by 18,657
The Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090
Diagnostic and Statistical Manual of Mental Disorders(DSM)
(2008) · Encyclopedia of Counseling · doi:10.4135/9781412963978.n182 · Cited by 10,830
Research works printed but not linked: 5
- Higgins JPT Green S Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011] 2011 London The Cochrane Collaboration
- Hoch E Friemel C Schneider M Cannabis: Potenzial und Risiko [Cannabis: Potential and Risks] 2018 Heidelberg Springer
- National Research C, Institute of Medicine Committee on the Prevention of Mental D, Substance Abuse Among Children Y, Young Adults: Research A, Promising I (2009) The National Academies Collection: Reports funded by National Institutes of Health. In: O’Connell ME, Boat T, Warner KE (eds) Preventing mental, emotional, and behavioral disorders among young people: progress and possibilities. National Academies Press (US) 20662125
- OCEBM The oxford levels of evidence 2011 2 Oxford Oxford Centre for Evidence-Based Medicine
- W orld Health Organization ICD-10: international statistical classification of diseases and related health problems/World Health Organization 2004 Geneva World Health Organization
Cited by
Cannabis use and cannabis use disorder
Connor, J. P., Stjepanović, D., Le Foll, B., Hoch, E., Budney, A. J., & Hall, W. D. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00247-4 · Cited by 552
Self-citationHall, W., Stjepanović, D., Caulkins, J., Lynskey, M., Leung, J., Campbell, G., & Degenhardt, L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31789-1 · Cited by 357
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
Gene-Environment Interactions in Schizophrenia: A Literature Review
Wahbeh, M. H., & Avramopoulos, D. (2021) · Genes · doi:10.3390/genes12121850 · Cited by 214
“Another group also found that there was an additive interaction between schizophrenia PRS scores and regular cannabis use [87].”
BackgroundCannabis, cannabinoids and health: a review of evidence on risks and medical benefits
Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01880-2 · Cited by 139
“In these studies, THC and/or CBD were administered with other pharmacotherapies and/or psychotherapy [15].”
Self-citationHeavy cannabis use, dependence and the brain: a clinical perspective
Kroon, E., Kuhns, L., Hoch, E., & Cousijn, J. (2020) · Addiction · doi:10.1111/add.14776 · Cited by 132
Self-citationThe Use of Alcohol, Tobacco, Illegal Drugs and Medicines
Atzendorf, J., Rauschert, C., Seitz, N., Lochbühler, K., & Kraus, L. (2019) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2019.0577 · Cited by 248
An endocannabinoid-regulated basolateral amygdala–nucleus accumbens circuit modulates sociability
Folkes, O. M., Báldi, R., Kondev, V., Marcus, D. J., Hartley, N. D., Turner, B. D., Ayers, J. K., Baechle, J. J., Misra, M. P., Altemus, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131752 · Cited by 119
“eCBs regulate several central nervous system functions, including motor control, repetitive behaviors, pain perception, anxiety, stress, learning and memory, and social behaviors (7, 8), all of which are implicated in ASDs (1).”
BackgroundThe therapeutic role of Cannabidiol in mental health: a systematic review
Khan, R. A., Naveed, S., Mian, N., Fida, A., Raafey, M. A., & Aedma, K. K. (2020) · Journal of Cannabis Research · doi:10.1186/s42238-019-0012-y · Cited by 126
“conducted an excellent systematic review that summarized four systematic reviews and 14 randomized controlled trials (RCTs), but did not consider non-clinical trial evidence (case reports and case series) (Hoch et al., 2019).”
BackgroundIftikhar, A., Zafar, U., Ahmed, W., Shabbir, M. A., Sameen, A., Sahar, A., Bhat, Z. F., Kowalczewski, P. Ł., Jarzębski, M., & Aadil, R. M. (2021) · Molecules · doi:10.3390/molecules26247699 · Cited by 98
The Association Between Cannabis Use and Schizophrenia: Causative or Curative? A Systematic Review
Patel, S., Khan, S., Saipavankumar, M., & Hamid, P. (2020) · Cureus · doi:10.7759/cureus.9309 · Cited by 125
Wolfe, D., Corace, K., Butler, C., Rice, D., Skidmore, B., Patel, Y. B., Thayaparan, P., Michaud, A., Hamel, C., Smith, A. M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281826 · Cited by 66
“Similar conclusions were observed in recent systematic reviews reporting findings for cannabis use for end-stage cancer [39, 41, 46, 50, 51], Alzheimer’s disease/dementia [37, 38, 47, 49, 51], and Parkinson’s disease [48].”
BackgroundResultSerious adverse effects of cannabidiol (CBD): a review of randomized controlled trials
Dos Santos, R. G., Guimarães, F. S., Crippa, J. A. S., Hallak, J. E. C., Rossi, G. N., Rocha, J. M., & Zuardi, A. W. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1754793 · Cited by 67
Weber, F. C., & Wetter, T. C. (2021) · Neuropsychobiology · doi:10.1159/000517329 · Cited by 76
Jugl, S., Okpeku, A., Costales, B., Morris, E., Alipour-Haris, G., Hincapie-Castillo, J., Stetten, N. E., Sajdeya, R., Keshwani, S., Joseph, V., et al. (2021) · Medical Cannabis and Cannabinoids · doi:10.1159/000515069 · Cited by 44
McKee, K. A., Hmidan, A., Crocker, C. E., Lam, R. W. M., Meyer, J. H., Crockford, D. N., Trépanier, A., Aitchison, K. J., & Tibbo, P. G. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.044 · Cited by 47
Cannabinoids for Agitation in Alzheimer's Disease
Outen, J. D., Burhanullah, M. H., Vandrey, R. G., Amjad, H., Harper, D. G., Patrick, R. E., May, R., Agronin, M., Forester, B. P., & Rosenberg, P. B. (2021) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.01.015 · Cited by 48
The role of cannabis in treating anxiety: an update
Ameringen, M. V., Zhang, J., Patterson, B. A., & Turna, J. (2019) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000566 · Cited by 81
Buprenorphine–cannabis interaction in patients undergoing opioid maintenance therapy
Vierke, C., Marxen, B., Böettcher, M., Hiemke, C., & Havemann‐Reinecke, U. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-01091-0 · Cited by 43
Medical Cannabis for the Treatment of Migraine in Adults: A Review of the Evidence
Okusanya, B. O., Lott, B. E., Ehiri, J. E., McClelland, J. D., & Rosales, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.871187 · Cited by 38
Hordowicz, M., Klimkiewicz, A., Jarosz, J., Wysocka, M., & Jastrzębska, M. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108652 · Cited by 45
Possible therapeutic applications of cannabis in the neuropsychopharmacology field
Fernández‐Ruíz, J., Galve‐Roperh, I., Sagredo, O., & Guzmán, M. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.01.013 · Cited by 40
Cannabis use and mental health: risks and benefits
Hall, W., Hoch, E., & Lorenzetti, V. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00986-2 · Cited by 32
Self-citationCosta, A. C., Joaquim, H. P. G., Pedrazzi, J. F. C., Pain, A. D. O., Duque, G., & Aprahamian, I. (2022) · Brain Sciences · doi:10.3390/brainsci12121596 · Cited by 43
“The authors reported insufficient evidence of cognitive improvement with THC, translating into a potential mean reduction of 1 point in the standardized Mini-Mental State Examination [89].”
BackgroundMarcolini, F., Ravaglia, A., Valenta, S. T., Bosco, G., Marconi, G., Ronchi, D. D., & Atti, A. R. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01006-y · Cited by 39
“…has been quite weak, especially in AN [25] , it has been suggested that patients with SE-ED could benefit from using some medications, especially those that induce weight gain, such as Olanzapine [25– 27] , or those that stimulate appetite, such as Dronabinol, a cannabinoid drug [28–30] .”
BackgroundTrkulja, V., & Barić, H. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9705-0_22 · Cited by 28
Rice, L. J., Cannon, L., Dadlani, N., Cheung, M. M. Y., Einfeld, S., Efron, D., Dossetor, D. R., & Elliott, E. J. (2023) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-023-02169-w · Cited by 39
Sandhu, H. S., Anderson, L. N., & Busse, J. W. (2019) · CMAJ Open · doi:10.9778/cmajo.20190008 · Cited by 32
Popow, C., Ohmann, S., & Plener, P. L. (2021) · Neuropsychiatrie · doi:10.1007/s40211-021-00395-9 · Cited by 36
Medicinal cannabis for psychiatry-related conditions: an overview of current Australian prescribing
Cairns, E. A., Benson, M. J., Bedoya‐Pérez, M. A., Macphail, S. L., Mohan, A., Cohen, R., Sachdev, P. S., & McGregor, I. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1142680 · Cited by 29
“, 2022) and also included in the larger systematic reviews of psychiatric conditions published in the past 3 years (Black et al., 2019; Bonaccorso et al., 2019; Hoch et al., 2019; Botsford et al., 2020; Khan et al., 2020; Sarris et al., 2020; Kloiber et al., 2021; Stanciu et al., 2021).”
BackgroundFischer, B., Hall, W., Fidalgo, T. M., Hoch, E., Foll, B. L., Medina‐Mora, M. E., Reimer, J., Tibbo, P. G., & Jutras‐Aswad, D. (2023) · Journal of Dual Diagnosis · doi:10.1080/15504263.2023.2226588 · Cited by 28
“Overall, reviews have suggested that CBD—even at high (e.g., 1,000–1,500mg/day) doses— is generally safe and well-tolerated, and it may alleviate cognitive symptoms in psychosis patients (Batalla et al., 2019; Davies & Bhattacharyya, 2019; Hoch et al., 2019; Sarris et al., 2020).”
BackgroundSelf-citationMedicinal cannabis: knowledge, beliefs, and attitudes of Colombian psychiatrists
Orjuela-Rojas, J. M., Orjuela, X. G., & Ocampo-Serna, S. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00083-z · Cited by 25
“…harmful connotations of cannabis in the field of mental health (Rey, 2002) could be changing with new and emerging safety and efficacy research (Hoch et al., 2019) and that, therefore, although psychiatrists are not inclined to use it for mental disorders at present, they are beginning to…”
BackgroundTreatment studies with cannabinoids in anorexia nervosa: a systematic review
Rosager, E. V., Møller, C., & Sjögren, M. (2020) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-020-00891-x · Cited by 23
The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis
Kopelli, E., Samara, M. T., Siargkas, A., Goulas, A., Papazisis, G., & Chourdakis, M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113246 · Cited by 24
Bioactive Hemp Clothing Modified with Cannabidiol (CBD) Cannabis sativa L. Extract
Zimniewska, M., Pawlaczyk, M., Romanowska, B., Gryszczyńska, A., Kwiatkowska, E., & Przybylska, P. (2021) · Materials · doi:10.3390/ma14206031 · Cited by 26
Kendzor, D. E., Ehlke, S. J., Boozary, L. K., Smith, M., & Cohn, A. M. (2022) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2022.101777 · Cited by 28
Argentination: A Silver Bullet for Cannabinoid Separation by Differential Mobility Spectrometry
Ieritano, C., Thomas, P., & Hopkins, W. S. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c01241 · Cited by 18
Wirksamkeit und Sicherheit von Cannabisarzneimitteln: Ergebnisse der CaPRis-Studie
CaPRis-Projektgruppe, Hoch, E., Friemel, C. M., Schneider, M., Pogarell, O. M., Hasan, A., & Preuss, U. W. (2019) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-019-02965-3 · Cited by 23
Self-citationBeneficial effects of cannabidiol from Cannabis
Lee, S., Lee, Y., Kim, Y., Kim, H. J., Rhyu, H., Yoon, K. M., Lee, C.-D., & Lee, S. (2024) · Applied Biological Chemistry · doi:10.1186/s13765-024-00867-w · Cited by 25
“Sativex is significant for reducing pain and convulsions in patients with multiple sclerosis [59].”
BackgroundMedical cannabis for children: Evidence and recommendations
Kelly, L. E., Rieder, M. J., & Finkelstein, Y. (2023) · Paediatrics & Child Health · doi:10.1093/pch/pxad078 · Cited by 40
Recent Approaches of Ocular Disease and Its Herbal Product Treatment: An Updates
Butola, K., Bisht, V., & Kumar, R. (2023) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.2.2.15 · Cited by 20
Developmental differences in the effects of CB1/2R agonist WIN55212-2 on extinction of learned fear
Bisby, M. A., Richardson, R., & Baker, K. (2019) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109834 · Cited by 17
The differential effects of medicinal cannabis on mental health: A systematic review
de Bode, N., Kroon, E., Sznitman, S. R., & Cousijn, J. (2025) · Clinical Psychology Review · doi:10.1016/j.cpr.2025.102581 · Cited by 18
Effects of cannabis regulation in Switzerland: Study protocol of a randomized controlled trial
Baltes‐Flueckiger, L., Steinauer, R., Meyer, M., Vogel, M., & Walter, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1139325 · Cited by 16
“Medical cannabis has been associated with improvements of symptoms of mental disorders, including anxiety, schizophrenia, and sleep (42, 43).”
BackgroundA Case Report of Cannabidiol Treatment of a Crohn's Disease Patient With Anxiety Disorder
Klier, C. M., de Gier, C., Felnhofer, A., Laczkovics, C., & Amminger, G. P. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001152 · Cited by 13
“fostered through certain practices, such as role play sessions with simulated patients(13); small pilot studies consider that compassion can also be taught within the undergraduate curriculum, simply by empowering students towitness compassionate acts.(14)Havingmore evidence on how these skills may influence adherence…”
BackgroundResultAminiLari, M., Busse, J. W., Turna, J., & MacKillop, J. M. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0128 · Cited by 12
Redonnet, B., Eren, F., Avenin, G., Melchior, M., & Mary‐Krause, M. (2025) · Addiction · doi:10.1111/add.16745 · Cited by 12
“…categorized into the following groups: all medical conditions, including SUDs [52, 60]; all psychiatric disorders, including SUDs [45, 46, 49 – 51, 55, 63]; only SUDs [53, 54, 56, 64]; only cannabis use disorders (CUD) [ 44, 58, 61, 62, 64]; only cannabis withdrawal symptoms (CWS) [ 59];…”
Ney, L. J., Akóṣílè, W., Davey, C. G., Pitcher, L., Felmingham, K. L., Mayo, L. M., Hill, M. N., & Strodl, E. S. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2276309 · Cited by 9
“While cannabis can have mood-elevating and anxiolytic effects for some individuals, others may experience increased anxiety or negative changes in mood [143,156], including increased apathy and amotivation [157].”
BackgroundLamonarca, J., Mintz, I., Bayarres, L., Kochen, S. S., & Oddo, S. A. (2024) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2024.110032 · Cited by 9
Gräfe, E. L., Reid, H. M. O., Shkolnikov, I., Conway, K., Kit, A., Acosta, C., & Christie, B. R. (2023) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2023.101076 · Cited by 10
Cannabinoids for Pain Control During Medical Abortion
Colwill, A. C., Alton, K., Bednarek, P. H., Bayer, L. L., Jensen, J. T., Garg, B., Beardsworth, K. M., & Edelman, A. B. (2020) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000003850 · Cited by 9
Effectiveness of Medical Cannabis for the Treatment of Depression: A Naturalistic Outpatient Study
Specka, M., Bonnet, U., Schmidberg, L. M., Wichmann, J. L., Keller, M., Scholze, C., & Scherbaum, N. (2024) · Pharmacopsychiatry · doi:10.1055/a-2215-6114 · Cited by 10
“Regarding the clinical impact of cannabis medication on mental disorders, a meta-analysis from 2019 revealed only scarce evidence to suggest that cannabinoids improve depressive disorders and symptoms [12].”
BackgroundMedicinal cannabis in the management of anxiety disorders: A systematic review
Roberts, L., Sorial, E., Budgeon, C. A., Lee, K., Preen, D. B., & Cumming, C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116552 · Cited by 12
“…psychiatric conditions such as depression, attention-deficit hyperactivity disorder (ADHD), bipolar, schizophrenia, psychosis, personality disorders (Botsford et al., 2020; Hoch et al., 2019; Sarris et al., 2020), these reviews reported mixed findings and highlighted the need for further research.”
Ono, K. E., Bearden, D. J., Lee, S. M., Moss, C. M., Kheder, A., Cernokova, I., Drane, D. L., & Gedela, S. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108872 · Cited by 11
Sleep-Related Cannabis Expectancy Questionnaire (SR-CEQ): Initial Development among College Students
Goodhines, P. A., LaRowe, L. R., Gellis, L. A., Ditre, J. W., & Park, A. (2020) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2020.1800151 · Cited by 7
Therapeutic Use of Hallucinogens
Wiltenburg, V. D., Prado, D. D. R., & Mendes, F. R. (2021) · Springer eBooks · doi:10.1007/978-3-030-62855-0_35 · Cited by 8
Gharbi, K. A., Bonomo, Y. A., & Hallinan, C. M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20054087 · Cited by 8
Preclinical behavioral and pharmacological treatments for enhancing fear extinction in adolescence
Wall, E. K., Virakorn, E. A., Baker, K., Cohen, E. M., & Richardson, R. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106090 · Cited by 7
“In adults, the short-term use of cannabis-based medications along with psychological treatment has been associated with reductions in mental health symptoms (Hoch et al., 2019; Roitman et al., 2014).”
The relationship between cannabis and anorexia nervosa: a scoping review
Rogers, C. I., & Pacanowski, C. R. (2023) · Journal of Eating Disorders · doi:10.1186/s40337-023-00887-9 · Cited by 7
“Cannabinoids, the chemical components of the cannabis plant, are of interest for AN as they not only have the potential to increase appetite, but also reduce anxiety [6, 7].”
BackgroundInfluentialStienrut, P., Pongpirul, K., Phutrakool, P., Savigamin, C., Sermsaksasithorn, P., Chanhom, O., Jeamjumrus, P., Pongchaichanon, P., Nootim, P., Soisamrong, M., et al. (2024) · Medical Cannabis and Cannabinoids · doi:10.1159/000540153 · Cited by 9
Cannabidiol As a Treatment for COVID-19 Symptoms? A Critical Review
Holst, M., Nowak, D., & Hoch, E. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2021.0135 · Cited by 8
“It is not clear whether these findings can be translated to CBD if used to treat patients with mild COVID-19– related respiratory symptoms.”
InfluentialSelf-citationEducation and Attitudes on Medical Cannabis in Family Medicine Residency Programs
Philbrick, A. M., Danner, C. C., Oyenuga, A., Pereira, C. R., Ricco, J. A., & Wendling, A. L. (2020) · Family Medicine · doi:10.22454/fammed.2020.645274 · Cited by 6
The Role of Medicinal Cannabis as an Emerging Therapy for Opioid Use Disorder
Le, K., Le, K. D. R., Nguyen, J., Hua, J., & Munday, S. (2024) · Pain and Therapy · doi:10.1007/s40122-024-00599-1 · Cited by 9
“Effects also vary between individuals based on factors such as the formulation of cannabis, dosage, potency and metabolism and tolerance of the individual [16, 86].”
BackgroundAssessing effects of Cannabis on various neuropathologies: A systematic review
Pathak, S., Jeyabalan, J. B., Liu, K., Cook, P., Lange, B., Kim, S., Nadar, R. M., Ward, K., Alexander, C. S. W., Kumar, A., et al. (2024) · Journal of Ayurveda and Integrative Medicine · doi:10.1016/j.jaim.2024.100911 · Cited by 8
Love, S., Rowland, B., & Armstrong, K. A. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310958 · Cited by 5
Ginati, Y. D., Madjar, N., Ben-Sheetrit, J., Lev‐Ran, S., Weizman, A., & Shoval, G. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1941444 · Cited by 5
“Similar to the contemporary trend in cannabinoids (Ferber et al. 2020; Hoch et al. 2019; Pinto et al. 2020; Shbiro et al. 2019), the potential therapeutic usage of hallucinogenic drugs in clinical psychiatry is studied extensively (Garcia-Romeu, Kersgaard, and Addy 2016; Garcia-Romeu and Richards…”
BackgroundCannabis Consumption Among Adults Aged 55–65 in Canada, 2018–2021
Wadsworth, E., Cristiano, N., Gabrys, R. L., Renard, J., & Hammond, D. G. (2023) · Journal of Drug Issues · doi:10.1177/00220426231190022 · Cited by 8
“However, the ef fi cacy of cannabis for anxiety and depression is limited and inconclusive (Black et al., 2019; Hoch et al., 2019).”
Evidence synthesis of medical cannabis research: current challenges and opportunities
Senator, B., Pardal, M., & Vandam, L. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01893-x · Cited by 9
Cannabis and non-psychotic mental disorders
Patten, S. B. (2020) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2020.09.006 · Cited by 8
Combinatorial approaches for treating neuropsychiatric social impairment
Don, W., Tsheringla, S., McPartland, J. C., & Allsop, S. A. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2021.0051 · Cited by 6
“Evidence for the viability of this approach can already be seen as studies have shown improvements of several symptoms, including social anxiety, when CBD-based medicine is given as an adjunct to pharmacotherapy or psychotherapy [247].”
Schott, M. (2019) · PAIN Reports · doi:10.1097/pr9.0000000000000774 · Cited by 6
Cooling, S., Bonomo, Y. A., Castle, D. J., & Hallinan, C. M. (2025) · Clinical Drug Investigation · doi:10.1007/s40261-025-01501-3 · Cited by 4
“Future research should focus on conducting high-quality, adequately powered trials with rigorous methodologies, standardised measures, and longer follow-up periods to provide more conclusive evidence. stress disorder (PTSD) [11, 12], psychotic disorders [13–15], and substance use disorders [7, 16].”
Strada, L., Korteling, S., Vergeer, M., & Oomen, P. E. (2025) · Journal of Cannabis Research · doi:10.1186/s42238-025-00355-y · Cited by 5
“Patient-reported outcomes from this study and others [36–38] suggest that people with anxiety, depression, PTSD, or other conditions can perceive cannabis as beneficial for symptom relief and overall wellbeing.”
Cannabinoids: Possible role in the pathophysiology and therapy of Gilles de la Tourette syndrome
Szejko, N., & Müller‐Vahl, K. (2022) · International review of movement disorders · doi:10.1016/bs.irmvd.2022.04.002 · Cited by 4
Authorizing medical cannabis for children
Rieder, M. J. (2020) · Paediatrics & Child Health · doi:10.1093/pch/pxaa024 · Cited by 3
“As well, there are potential developmental issues in children requiring fulsome consideration and discussion (1,6).”
BackgroundRecent Advancement in Self Emulsifing Drug Delivery System
Bist, V. L., & Faruk, A. (2023) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.2.2.14 · Cited by 3
Lucas, P., Boyd, S. C., Milloy, M., & Walsh, Z. (2021) · Journal of Cannabis Research · doi:10.1186/s42238-021-00089-7 · Cited by 3
Cannabis Use and Mental Health: Paradoxes of Medicalization
Dolphin, W., & Newhart, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-83745-7_11 · Cited by 3
Lazor, T., Mehra, K., Rup, J., Wiese, J. L., Watson, T. M., Hamilton, H., Sockalingam, S., Kloiber, S. M., Margolese, S. L., Wells, S. L., et al. (2025) · Contemporary Drug Problems · doi:10.1177/00914509251394526 · Cited by 2
“…use cannabis to alleviate symptoms (Andries et al., 2015; Bisaga et al., 2015; Hoch et al., 2019; Jetly et al., 2015); however, a systematic review of randomized controlled trials found mixed evidence on the effectiveness of cannabis for the treatment of mental health disorders (Hoch et al., 2019).”
Empirical Analysis of the Volatility of Stock Market Based on the Improved GARCH Model
祝, 人. (2020) · Advances in Applied Mathematics · doi:10.12677/aam.2020.92017 · Cited by 2
Situación actual de Cannabis sativa, beneficios terapéuticos y reacciones adversas
Rodríguez-Venegas, E. D. L. C., & Fontaine-Ortiz, J. E. (2020) · Revista Habanera de Ciencias Médicas · Cited by 9
Cannabinoids - Recent Perspectives and Applications in Human Health
JAMES, S. P. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100996 · Cited by 3
Treatment of Sleep Disorders in Specific Psychiatric Diseases
Wetter, T. C., & Steiger, A. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_451 · Cited by 2
Skubel, T., Czarnota, J., Dobrzyński, M., Kopystecka, A., Kozioł, I., Drozd, M., Rybak, N., & Patryn, R. K. (2022) · Journal of Education Health and Sport · doi:10.12775/jehs.2022.12.08.093 · Cited by 1
Cannabis Use in the Peripartum Period
Michel, A. D., & King, D. D. (2025) · Nursing for Women s Health · doi:10.1016/j.nwh.2025.04.005 · Cited by 1
Rundle, S. M., Iraniparast, M., & Hammond, D. G. (2026) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2026.101373 · Cited by 2
Dawson, D., Stjepanović, D., Leung, J., Lim, C. C. W., Hall, W., Lorenzetti, V., Chan, G., & Hammond, D. G. (2026) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2026.113124 · Cited by 1
“These findings may warrant concern as there is limited evidence that cannabis is effective in treating anxiety (Wilson et al., 2026; Hoch et al., 2019) and paradoxically, anxiety is a common side effect of using cannabis, particularly products with higher levels of THC (Hoch et al., 2024).”
Treatments with cannabinoids and brain development
Schönhofen, P., de Vargas, D. M., Parsons, R. B., & Klamt, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817988-8.00036-1 · Cited by 1
Marijuana Policies in Drug Treatment Courts
Lu, R. (2023) · Journal of Drug Issues · doi:10.1177/00220426231163796 · Cited by 1
“A later systematic review that focuses more closely on mental illnesses also concluded that the amount of evidence showing cannabis-based medicines can be used to treat mental disorders effectively and safely is still small (Hoch et al., 2019).”
BackgroundMedicinal Uses of Cannabis sativa and Its Derivatives
Nabi, Z., Manzoor, J., & Sharma, A. (2023) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-6684-5718-4.ch004 · Cited by 2
Medical use of cannabis: Applications to Tourette syndrome
Szejko, N., & Müller‐Vahl, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-90036-2.00021-1 · Cited by 1
Zeiger, J. S., & Conner, B. T. (2024) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-024-01384-z · Cited by 1
“Research on links between cannabis use and psychological distress are generally mixed (McBain et al., 2020) which may result from how cannabis use is measured or may be due to the lack of research regarding how to dose using cannabis to treat medical or mental health conditions (Hoch et al., 2019).”
Treatment of Sleep Disorders in Specific Psychiatric Diseases
Wetter, T. C., & Steiger, A. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_451-1 · Cited by 2
The Research Progress of Treatment of Several Mental Disorders Using Cannabis Drugs (THC and CBD)
周, 小. (2020) · Advances in Clinical Medicine · doi:10.12677/acm.2020.102020
Prädiktoren und Auswirkungen von Ermittlungsverfahren wegen Cannabis
Hanewinkel, R., Seidel, A.-K., & Morgenstern, M. (2020) · Das Gesundheitswesen · doi:10.1055/a-1160-5690
Cannabisarznei zur Behandlung psychischer Störungen
Hoch, E., Preuss, U. W., & Pogarell, O. M. (2020) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-020-1271-z
Self-citationArora, P., Johnson, A. J., Jayasekare, R. R., & Desai, K. R. (2021) · Journal of Public Health Policy · doi:10.1057/s41271-021-00282-1
The use of psychoactive substances in the treatment of mental disorders
Karaś-Ruszczyk, K., Groblińska, K., Szczygieł, K., & Samochowiec, J. (2021) · Alcoholism and Drug Addiction · doi:10.5114/ain.2021.111791 · Cited by 2
Cannabis Medicines: Guidance for the Selection, Purchase and Supply for Clinical Trials
Galettis, P., Barlow, J., Boublik, J. H., Capra, S., Galettis, R., Graham, M., Hill, C., Mavor, P., Nikolajevic‐Sarunac, J., Richards, R., et al. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.105682
Cannabis for Opioid Use Disorder
Palylyk-Colwell, E., & Bailey, S. M. (2022) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2022.457
“…Limitations The review authors declared conflict of interest (of which there were none) The source of the funding for the review was provided Hoch et al. (2019)15 The review authors stated that the review followed guidance published by the Centre for Reviews and Dissemination and the…”
BackgroundInfluential
Metadata
- Authors
- Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O.
- Affiliations
- LMU Klinikum (DE)
- Martin Luther University Halle-Wittenberg (DE)
- Corresponding author
- Hoch, Eva
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2019-01-31
- Volume
- 269
- Issue
- 1
- Pages
- 87-105
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- PMC
- PMC6595000
- OpenAlex
- W2912950775
- Cited by
- 131
- References
- 92
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 17 · 2023: 22 · 2022: 22 · 2021: 20 · 2020: 18 · 2019: 11
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Update notices
- correction (2019-04-05)
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Bundesministerium f?r Gesundheit
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plant Extracts Effects
- Keywords
- medical cannabis, cannabis-based medicines, mental illness, schizophrenia, psychosis, post-traumatic stress disorder, social anxiety, anorexia nervosa, attention deficit hyperactivity disorder, Tourette syndrome, dementia, THC, CBD, adjunctive therapy, efficacy, safety, adverse effects
- MeSH terms
- Mental Disorders, Cannabidiol, Humans, Dronabinol, Cannabinoid Receptor Modulators, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.